Table 2.

Adverse events during treatment with placebo or propionate

	Placebo (n = 31)	Propionate (n = 31)	Total (n = 62)
Any adverse event, n (%)
No	20 (64.5)	24 (77.4)	44 (71.0)
Yes	11 (35.5)	7 (22.6)	18 (29.0)
Adverse event, n (%)
Abdominal pain	1 (3.2)	0 (0.0)	1 (1.6)
Abdominal pain and nausea	0 (0.0)	1 (3.2)	1 (1.6)
Acute gastroenteritis	1 (3.2)	0 (0.0)	1 (1.6)
Bipolar disorder	1 (3.2)	0 (0.0)	1 (1.6)
Cold	1 (3.2)	0 (0.0)	1 (1.6)
Diarrhoea	1 (3.2)	0 (0.0)	1 (1.6)
Diarrhoea and cephalgia	0 (0.0)	1 (3.2)	1 (1.6)
Flatulence	1 (3.2)	1 (3.2)	2 (3.2)
Gastroenteritis	1 (3.2)	0 (0.0)	(1.6)
Gastroesophageal reflux	1 (3.2)	1 (3.2)	2 (3.2)
Chest pain and gastroesophageal reflux	1 (3.2)	0 (0.0)	1 (1.6)
Nausea	1 (3.2)	2 (6.5)	3 (4.8)
Nausea and abdominal pain and cephalgia	0 (0.0)	1 (3.2)	(1.6)
Vertigo	1 (3.2)	0 (0.0)	1 (1.6)
Elevation of liver enzymes
Males: AST => 50, females: AST => 35
Yes	4 (13.8)	0 (0.0)	4 (6.9)
No	25 (86.2)	29 (100.0)	54 (93.1)
Missing	2 (6.45)	2 (6.45)	4 (6.45)
Males: ALT => 41, females: AST => 31
Yes	4 (13.8)	5 (17.2)	4 (6.9)
No	25 (86.2)	24 (82.8)	49 (84.5)
Missing	2 (6.4)	2 (6.45)	4 (6.45)

There were no significant differences between the two groups.